Physician profile
Michael E Rau
NPI 1467496216
$2,425.30
in general payments reported to CMS, 2019-2025
23 companies · $16.82 in 2025
The $16.82 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $386 · 2021: $680 · 2022: $509 · 2023: $218 · 2024: $41.84 · 2025: $16.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $276.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $388.88 | 2019-2022 | |
| Abbvie INC. | $298.04 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.00 | 2019-2023 | Jardiance |
| Amgen INC. | $201.22 | 2019-2022 | |
| Lilly USA, LLC | $190.00 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $188.37 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $179.49 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $101.76 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.14 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.99 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $61.38 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $57.79 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $51.75 | 2021-2022 | |
| Eisai INC. | $46.77 | 2021 | |
| Sanofi-Aventis U.S. LLC | $38.63 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $37.73 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.60 | 2022 | |
| Amarin Pharma, INC. | $28.69 | 2021 | |
| Glaxosmithkline, LLC. | $28.59 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Nevro Corp. | $17.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.43 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.75 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.